Mesenchymal stem cell-derived extracellular vesicles alone or in conjunction with a SDKP-conjugated self-assembling peptide improve a rat model of myocardial infarction.
Actins
/ genetics
Animals
Animals, Newborn
Antigens, CD
/ genetics
Antigens, Differentiation, Myelomonocytic
/ genetics
Biological Transport
Biomarkers
/ metabolism
Disease Models, Animal
Extracellular Vesicles
/ metabolism
Gene Expression
Humans
Hydrogels
/ administration & dosage
Hydrogen Peroxide
/ pharmacology
Injections, Intramuscular
Mesenchymal Stem Cells
/ chemistry
Mice
Myocardial Infarction
/ genetics
Myocardium
/ metabolism
Myocytes, Cardiac
/ cytology
Oxidative Stress
Peptides
/ administration & dosage
Primary Cell Culture
Rats
Extracellular vesicles
Myocardial infarction
Self-assembling peptide hydrogel
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
16 04 2020
16 04 2020
Historique:
received:
15
01
2020
accepted:
01
02
2020
pubmed:
15
2
2020
medline:
21
10
2020
entrez:
15
2
2020
Statut:
ppublish
Résumé
The aim of this study was to investigate the cardiac repair effect of human bone marrow mesenchymal stromal cells-derived extracellular vesicles (MSC-EVs) after intramyocardial injection in free form or encapsulated within a self-assembling peptide hydrogel modified with SDKP motif, in a rat model of myocardial infarction (MI). MSC-EVs were isolated by ultracentrifuge and characterized for physical parameters and surface proteins. Furthermore, cellular uptake and cardioprotective effects of MSC-EVs were evaluated in vitro using neonatal mouse cardiomyocytes (NMCMs). In vivo effects of MSC-EVs on cardiac repair were studied in rat MI model by comparing the vehicle group (injected with PBS), EV group (injected with MSC-EVs) and Gel + EV group (injected with MSC-EVs encapsulated in (RADA) We observed the uptake of MSC-EVs into NMCMs which led to NMCMs protection against H These data demonstrated that MSC-EVs can be used alone as a potent therapeutic agent for improvement of myocardial infarction.
Identifiants
pubmed: 32057366
pii: S0006-291X(20)30269-2
doi: 10.1016/j.bbrc.2020.02.009
pii:
doi:
Substances chimiques
Actins
0
Antigens, CD
0
Antigens, Differentiation, Myelomonocytic
0
Biomarkers
0
CD68 protein, rat
0
Hydrogels
0
Peptides
0
smooth muscle actin, rat
0
Hydrogen Peroxide
BBX060AN9V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
903-909Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.